Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zavegepant Pharmacokinetics in Healthy Chinese Adults
NCT05960032Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zavegepant in migraine, sponsored by Pfizer. Primary endpoints: Maximum Plasma Concentration (Cmax) of Zavegepant, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Zavegepant and 1 more. Started Oct 2023; status: completed.
02
Drugs
zavegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05960032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05960032.